Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

Abstract

Sibutramine treatment in obesity results in significantly greater weight reduction compared with placebo, although weight loss with sibutramine may be accompanied by small but statistically significant mean increases in blood pressure (BP). This 52-week, placebo-controlled, double-blind, randomised study investigated the effects of sibutramine 20 mg once daily or placebo on body weight in 220 obese (body mass index (BMI) 27–40 kg/m2), hypertensive patients. At randomisation, hypertension was well controlled (95 mm Hg diastolic blood pressure (DBP)) with an angiotensin-converting enzyme (ACE) inhibitor, with or without concomitant thiazide diuretic therapy. Therapy for hypertension continued for the 52 weeks of the study. Sibutramine 20 mg produced significantly greater weight loss compared with placebo: 4.5 kg with sibutramine compared with 0.4 kg with placebo (last observation carried forward (LOCF); P 0.05). A total of 62 patients (42.8%) treated with sibutramine lost 5% of their body weight compared with six patients (8.3%) treated with placebo; 19 patients (13.1%) treated with sibutramine lost 10% of their body weight compared with two patients (2.8%) treated with placebo (LOCF; P 0.05 for both comparisons). Hypertension remained well controlled for the 52 weeks of the study with both sibutramine and placebo treatment. After 52 weeks, the differences between placebo treatment and sibutramine treatment for both mean supine systolic blood pressure (SBP) and DBP were approximately 3 mm Hg: mean DBP was 82.8 mm Hg with placebo treatment compared with 85.5 mm Hg with sibutramine treatment (LOCF; P = 0.004) and mean SBP was 130.4 mm Hg with placebo compared with 133.1 mm Hg with sibutramine (LOCF; P = 0.0497; both comparisons, sibutramine vs placebo). The mean increases in SBP and DBP did not appear to change the overall risk category for coronary heart disease end points. Changes in pulse rate at week 52 were a decrease of 0.3 beats per minute (bpm) for placebo treatment compared with an increase of 5.7 bpm for sibutramine treatment (P < 0.001). Mandated withdrawals from the study due to protocol-defined changes in BP were not statistically different between the two treatment groups. Greater favourable changes in lipid profile, serum glucose, and uric acid could be accounted for by greater weight losses occurring in the sibutramine treatment group. Sibutramine was well tolerated. This study indicates that in obese patients whose hypertension is well controlled at the outset with an ACE inhibitor, with or without concomitant thiazide diuretic therapy, sibutramine safely and effectively achieves weight loss without compromising good BP control.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Eckel RH and for the Nutrition Committee. Obesity and heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association Circulation 1997 96: 3248–3250

    Article  CAS  PubMed  Google Scholar 

  2. Rimm EB et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men Am J Epidemiol 1995 141: 1117–1127

    Article  CAS  PubMed  Google Scholar 

  3. Van Itallie TB . Health implications of overweight and obesity in the United States Ann Intern Med 1985 103: 983–988

    Article  CAS  PubMed  Google Scholar 

  4. Calle EE et al. Body-mass index and mortality in a prospective cohort of U.S. adults N Engl J Med 1999 341: 1097–1105

    Article  CAS  PubMed  Google Scholar 

  5. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults Arch Intern Med 1998 158: 1855–1867

  6. Bray GA et al. Sibutramine produces dose-related weight loss Obes Res 1999 7: 189–198

    Article  CAS  PubMed  Google Scholar 

  7. James WPT et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial Lancet 2000 356: 2119–2125

    Article  CAS  PubMed  Google Scholar 

  8. Hansen DL et al. Thermogenic effects of sibutramine in humans Am J Clin Nutr 1998 68: 1180–1186

    Article  CAS  PubMed  Google Scholar 

  9. Eckel RH, Krauss RM for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease Circulation 1998 97: 2099–2100

    Article  CAS  PubMed  Google Scholar 

  10. Goldstein DJ . Beneficial health effects of modest weight loss Int J Obes Relat Metab Disord 1992 16: 397–415

    CAS  PubMed  Google Scholar 

  11. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 1997 157: 2413–2446

  12. Luque CA, Rey JA . Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment ofobesity Ann Pharmacother 1999 33: 968–978

    Article  CAS  PubMed  Google Scholar 

  13. Apfelbaum M et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am J Med 1999 106: 179–184

    Article  CAS  PubMed  Google Scholar 

  14. Hansson L . The Hypertension Optimal Treatment study and the importance of lowering blood pressure J Hypertens 1999 17 (Suppl 1): S9–S13

    Google Scholar 

  15. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin inpatients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 1998 351: 1755–1762

    Article  CAS  PubMed  Google Scholar 

  16. Finer N et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor Int J Obes 2000 24: 306–313

    Article  CAS  Google Scholar 

  17. Fujioka K et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obesepatients with type 2 diabetes mellitus Diabetes Obes Metab 2000 2: 175–187

    Article  CAS  PubMed  Google Scholar 

  18. Lauterbach K, Evers T . Framingham analysis: coronary heart disease risk reduction with weight loss in obesity on sibutramine treatment. [abstract PB 83] Obes Res 2000 8 (Suppl 1): 88S

    Google Scholar 

  19. McMahon FG et al. Efficacy and safety of sibutramine in obese white and African Americanpatients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial Arch Intern Med 2000 160: 2185–2191

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Abbott Laboratories, Abbott Park, Illinois, USA. Study team members: Bramah Singh MD, PhD; F Gilbert McMahon, MD; Arshag Mooradian, MD; Steven P Weinstein, MD, PhD; Ken Fujioka, MD; Everton Rowe, PhD; Kate Ernst.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to F G McMahon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McMahon, F., Weinstein, S., Rowe, E. et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16, 5–11 (2002). https://doi.org/10.1038/sj.jhh.1001298

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001298

Keywords

This article is cited by

Search

Quick links